Loading…

Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy

Although the incidence of immune checkpoint inhibitor (ICI)-related cardiovascular (CV) toxicity is low, the overall burden of CV events after ICI is unknown. Risk factors for CV events after ICI have yet to be identified. We sought to evaluate the association between vascular calcification on routi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2021-01, Vol.322, p.177-182
Main Authors: Schiffer, Walter B., Deych, Elena, Lenihan, Daniel J., Zhang, Kathleen W.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c339t-60b862fc542eb3d7f59d81013f62ede3b92c4e4f41322ecb3eb9c6be13b8a8b73
cites cdi_FETCH-LOGICAL-c339t-60b862fc542eb3d7f59d81013f62ede3b92c4e4f41322ecb3eb9c6be13b8a8b73
container_end_page 182
container_issue
container_start_page 177
container_title International journal of cardiology
container_volume 322
creator Schiffer, Walter B.
Deych, Elena
Lenihan, Daniel J.
Zhang, Kathleen W.
description Although the incidence of immune checkpoint inhibitor (ICI)-related cardiovascular (CV) toxicity is low, the overall burden of CV events after ICI is unknown. Risk factors for CV events after ICI have yet to be identified. We sought to evaluate the association between vascular calcification on routine baseline computed tomography (CT) imaging and CV events following ICI. This was a single-center, retrospective cohort study of 76 patients referred to Cardio-Oncology with prior ICI treatment. Coronary and aortic calcification on non-gated chest and abdominal CT imaging were qualitatively assessed. The association of baseline clinical parameters and vascular calcification with symptomatic heart failure (HF), acute coronary syndrome, myocarditis, symptomatic arrhythmia, or pericardial effusion after ICI was evaluated. Over 11 months of follow-up, there were 80 CV events that occurred in 49 patients. Worse coronary and aortic calcification on pre-treatment CT imaging was seen in patients with a CV event (p = .018 and p = .014, respectively). There were no differences in traditional CV risk factors between those with and without a CV event. Eighteen patients (37%) were restarted on ICI therapy after a non- myocarditis or symptomatic systolic HF CV event without recurrent events or mortality over 13 months of follow-up. Symptomatic HF was the most common CV event seen after ICI therapy. Worse coronary and aortic calcification on baseline CT imaging was associated with CV events following ICI. With careful clinical evaluation, selected patients may be re-treated with ICI following a non- myocarditis or symptomatic systolic HF CV event. •A broad range of cardiovascular events may be seen in patients receiving immune checkpoint inhibitor (ICI) therapy.•Vascular calcification on baseline non-gated CT scans are associated with the occurrence of cardiovascular events on ICI therapy.•Selected patients may be re-treated with ICI after a non-myocarditis or symptomatic systolic heart failure event on ICI therapy.
doi_str_mv 10.1016/j.ijcard.2020.08.024
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2434758449</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527320335518</els_id><sourcerecordid>2434758449</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-60b862fc542eb3d7f59d81013f62ede3b92c4e4f41322ecb3eb9c6be13b8a8b73</originalsourceid><addsrcrecordid>eNp9kD1v2zAURYmgAeI6_QcdOHaRSpGURC0FAiMfBQJ0aWeCfHqCnyOTDkk7yL-PDGfu9JZz78M9jH1vRN2Ipvu5q2kHLo21FFLUwtRC6iu2akyvq6Zv9Re2WrC-amWvbtjXnHdCCD0MZsXSJqYYXHrnLozcxVQIOLgZaCJwhWLgLiF3OUcgV3Dkb1S2_PyN4sllOM4ucTxhKJkvMO33x4Actggvh0ihcApb8lRi4mWLyR3eb9n15OaM3z7vmv17uP-7eaqe_zz-3tw9V6DUUKpOeNPJCVot0auxn9phNMtcNXUSR1R-kKBRT7pRUiJ4hX6AzmOjvHHG92rNflx6Dym-HjEXu6cMOM8uYDxmK7XSfWu0HhZUX1BIMeeEkz0k2i9WbCPsWbHd2Ytie1ZshbGL4iX26xLDZcaJMNkMhAFwpIRQ7Bjp_wUfcsOJ_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2434758449</pqid></control><display><type>article</type><title>Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy</title><source>ScienceDirect Journals</source><creator>Schiffer, Walter B. ; Deych, Elena ; Lenihan, Daniel J. ; Zhang, Kathleen W.</creator><creatorcontrib>Schiffer, Walter B. ; Deych, Elena ; Lenihan, Daniel J. ; Zhang, Kathleen W.</creatorcontrib><description>Although the incidence of immune checkpoint inhibitor (ICI)-related cardiovascular (CV) toxicity is low, the overall burden of CV events after ICI is unknown. Risk factors for CV events after ICI have yet to be identified. We sought to evaluate the association between vascular calcification on routine baseline computed tomography (CT) imaging and CV events following ICI. This was a single-center, retrospective cohort study of 76 patients referred to Cardio-Oncology with prior ICI treatment. Coronary and aortic calcification on non-gated chest and abdominal CT imaging were qualitatively assessed. The association of baseline clinical parameters and vascular calcification with symptomatic heart failure (HF), acute coronary syndrome, myocarditis, symptomatic arrhythmia, or pericardial effusion after ICI was evaluated. Over 11 months of follow-up, there were 80 CV events that occurred in 49 patients. Worse coronary and aortic calcification on pre-treatment CT imaging was seen in patients with a CV event (p = .018 and p = .014, respectively). There were no differences in traditional CV risk factors between those with and without a CV event. Eighteen patients (37%) were restarted on ICI therapy after a non- myocarditis or symptomatic systolic HF CV event without recurrent events or mortality over 13 months of follow-up. Symptomatic HF was the most common CV event seen after ICI therapy. Worse coronary and aortic calcification on baseline CT imaging was associated with CV events following ICI. With careful clinical evaluation, selected patients may be re-treated with ICI following a non- myocarditis or symptomatic systolic HF CV event. •A broad range of cardiovascular events may be seen in patients receiving immune checkpoint inhibitor (ICI) therapy.•Vascular calcification on baseline non-gated CT scans are associated with the occurrence of cardiovascular events on ICI therapy.•Selected patients may be re-treated with ICI after a non-myocarditis or symptomatic systolic heart failure event on ICI therapy.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2020.08.024</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Acute coronary syndrome ; Arrhythmia ; Heart failure ; Immunotherapy ; Myocarditis ; Pericardial disease</subject><ispartof>International journal of cardiology, 2021-01, Vol.322, p.177-182</ispartof><rights>2020 Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-60b862fc542eb3d7f59d81013f62ede3b92c4e4f41322ecb3eb9c6be13b8a8b73</citedby><cites>FETCH-LOGICAL-c339t-60b862fc542eb3d7f59d81013f62ede3b92c4e4f41322ecb3eb9c6be13b8a8b73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Schiffer, Walter B.</creatorcontrib><creatorcontrib>Deych, Elena</creatorcontrib><creatorcontrib>Lenihan, Daniel J.</creatorcontrib><creatorcontrib>Zhang, Kathleen W.</creatorcontrib><title>Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy</title><title>International journal of cardiology</title><description>Although the incidence of immune checkpoint inhibitor (ICI)-related cardiovascular (CV) toxicity is low, the overall burden of CV events after ICI is unknown. Risk factors for CV events after ICI have yet to be identified. We sought to evaluate the association between vascular calcification on routine baseline computed tomography (CT) imaging and CV events following ICI. This was a single-center, retrospective cohort study of 76 patients referred to Cardio-Oncology with prior ICI treatment. Coronary and aortic calcification on non-gated chest and abdominal CT imaging were qualitatively assessed. The association of baseline clinical parameters and vascular calcification with symptomatic heart failure (HF), acute coronary syndrome, myocarditis, symptomatic arrhythmia, or pericardial effusion after ICI was evaluated. Over 11 months of follow-up, there were 80 CV events that occurred in 49 patients. Worse coronary and aortic calcification on pre-treatment CT imaging was seen in patients with a CV event (p = .018 and p = .014, respectively). There were no differences in traditional CV risk factors between those with and without a CV event. Eighteen patients (37%) were restarted on ICI therapy after a non- myocarditis or symptomatic systolic HF CV event without recurrent events or mortality over 13 months of follow-up. Symptomatic HF was the most common CV event seen after ICI therapy. Worse coronary and aortic calcification on baseline CT imaging was associated with CV events following ICI. With careful clinical evaluation, selected patients may be re-treated with ICI following a non- myocarditis or symptomatic systolic HF CV event. •A broad range of cardiovascular events may be seen in patients receiving immune checkpoint inhibitor (ICI) therapy.•Vascular calcification on baseline non-gated CT scans are associated with the occurrence of cardiovascular events on ICI therapy.•Selected patients may be re-treated with ICI after a non-myocarditis or symptomatic systolic heart failure event on ICI therapy.</description><subject>Acute coronary syndrome</subject><subject>Arrhythmia</subject><subject>Heart failure</subject><subject>Immunotherapy</subject><subject>Myocarditis</subject><subject>Pericardial disease</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kD1v2zAURYmgAeI6_QcdOHaRSpGURC0FAiMfBQJ0aWeCfHqCnyOTDkk7yL-PDGfu9JZz78M9jH1vRN2Ipvu5q2kHLo21FFLUwtRC6iu2akyvq6Zv9Re2WrC-amWvbtjXnHdCCD0MZsXSJqYYXHrnLozcxVQIOLgZaCJwhWLgLiF3OUcgV3Dkb1S2_PyN4sllOM4ucTxhKJkvMO33x4Actggvh0ihcApb8lRi4mWLyR3eb9n15OaM3z7vmv17uP-7eaqe_zz-3tw9V6DUUKpOeNPJCVot0auxn9phNMtcNXUSR1R-kKBRT7pRUiJ4hX6AzmOjvHHG92rNflx6Dym-HjEXu6cMOM8uYDxmK7XSfWu0HhZUX1BIMeeEkz0k2i9WbCPsWbHd2Ytie1ZshbGL4iX26xLDZcaJMNkMhAFwpIRQ7Bjp_wUfcsOJ_g</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Schiffer, Walter B.</creator><creator>Deych, Elena</creator><creator>Lenihan, Daniel J.</creator><creator>Zhang, Kathleen W.</creator><general>Elsevier B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20210101</creationdate><title>Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy</title><author>Schiffer, Walter B. ; Deych, Elena ; Lenihan, Daniel J. ; Zhang, Kathleen W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-60b862fc542eb3d7f59d81013f62ede3b92c4e4f41322ecb3eb9c6be13b8a8b73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acute coronary syndrome</topic><topic>Arrhythmia</topic><topic>Heart failure</topic><topic>Immunotherapy</topic><topic>Myocarditis</topic><topic>Pericardial disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Schiffer, Walter B.</creatorcontrib><creatorcontrib>Deych, Elena</creatorcontrib><creatorcontrib>Lenihan, Daniel J.</creatorcontrib><creatorcontrib>Zhang, Kathleen W.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Schiffer, Walter B.</au><au>Deych, Elena</au><au>Lenihan, Daniel J.</au><au>Zhang, Kathleen W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy</atitle><jtitle>International journal of cardiology</jtitle><date>2021-01-01</date><risdate>2021</risdate><volume>322</volume><spage>177</spage><epage>182</epage><pages>177-182</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><abstract>Although the incidence of immune checkpoint inhibitor (ICI)-related cardiovascular (CV) toxicity is low, the overall burden of CV events after ICI is unknown. Risk factors for CV events after ICI have yet to be identified. We sought to evaluate the association between vascular calcification on routine baseline computed tomography (CT) imaging and CV events following ICI. This was a single-center, retrospective cohort study of 76 patients referred to Cardio-Oncology with prior ICI treatment. Coronary and aortic calcification on non-gated chest and abdominal CT imaging were qualitatively assessed. The association of baseline clinical parameters and vascular calcification with symptomatic heart failure (HF), acute coronary syndrome, myocarditis, symptomatic arrhythmia, or pericardial effusion after ICI was evaluated. Over 11 months of follow-up, there were 80 CV events that occurred in 49 patients. Worse coronary and aortic calcification on pre-treatment CT imaging was seen in patients with a CV event (p = .018 and p = .014, respectively). There were no differences in traditional CV risk factors between those with and without a CV event. Eighteen patients (37%) were restarted on ICI therapy after a non- myocarditis or symptomatic systolic HF CV event without recurrent events or mortality over 13 months of follow-up. Symptomatic HF was the most common CV event seen after ICI therapy. Worse coronary and aortic calcification on baseline CT imaging was associated with CV events following ICI. With careful clinical evaluation, selected patients may be re-treated with ICI following a non- myocarditis or symptomatic systolic HF CV event. •A broad range of cardiovascular events may be seen in patients receiving immune checkpoint inhibitor (ICI) therapy.•Vascular calcification on baseline non-gated CT scans are associated with the occurrence of cardiovascular events on ICI therapy.•Selected patients may be re-treated with ICI after a non-myocarditis or symptomatic systolic heart failure event on ICI therapy.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.ijcard.2020.08.024</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-5273
ispartof International journal of cardiology, 2021-01, Vol.322, p.177-182
issn 0167-5273
1874-1754
language eng
recordid cdi_proquest_miscellaneous_2434758449
source ScienceDirect Journals
subjects Acute coronary syndrome
Arrhythmia
Heart failure
Immunotherapy
Myocarditis
Pericardial disease
title Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T00%3A31%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Coronary%20and%20aortic%20calcification%20are%20associated%20with%20cardiovascular%20events%20on%20immune%20checkpoint%20inhibitor%20therapy&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Schiffer,%20Walter%20B.&rft.date=2021-01-01&rft.volume=322&rft.spage=177&rft.epage=182&rft.pages=177-182&rft.issn=0167-5273&rft.eissn=1874-1754&rft_id=info:doi/10.1016/j.ijcard.2020.08.024&rft_dat=%3Cproquest_cross%3E2434758449%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c339t-60b862fc542eb3d7f59d81013f62ede3b92c4e4f41322ecb3eb9c6be13b8a8b73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2434758449&rft_id=info:pmid/&rfr_iscdi=true